Literature DB >> 25685851

A Human Papillomavirus Type 16 E6 52-62 CD4 T-Cell Epitope Restricted by the HLA-DR11 Molecule Described in an Epitope Hotspot.

Hannah N Coleman1, Xuelian Wang2, William W Greenfield3, Mayumi Nakagawa1.   

Abstract

Cell-mediated immune responses to the human papillomavirus type 16 (HPV 16) E6 protein have been shown to be important in viral clearance and in regression of cervical lesions. Here, detailed analyses of a novel HPV 16 E6 CD4 T-cell epitope from a subject with cervical intraepithelial neoplasia 1 are described. This subject had demonstrated HPV 16 CD4 T-cell responses to multiple regions within the E6 protein. Isolation and cloning of CD4 T-cells were performed by magnetic selection of interferon-γ secreting cells and limiting dilution. A single HPV 16-specific T-cell clone isolated was shown to have a specificity to HPV 16 E6 52-62 restricted by the HLA-DR11 molecule. Homologous sequences (≥70% amino acid homology) were identified for HPV types 31, 33, 45, 58, 73, but cross-recognition was demonstrated only for HPV 45. Based on work performed by our group and others, it is known that this short peptide contains multiple CD4 and CD8 T-cell HPV epitopes and would be an ideal region to incorporate into a design of vaccines and immunotherapies against HPV-associated malignancies.

Entities:  

Keywords:  CD4; Epitope; Hotspot; Human Papillomavirus; T-cells

Year:  2014        PMID: 25685851      PMCID: PMC4326013          DOI: 10.15406/moji.2014.01.00018

Source DB:  PubMed          Journal:  MOJ Immunol        ISSN: 2373-4442


  22 in total

1.  Patterns of CD8 T-cell epitopes within the human papillomavirus type 16 (HPV 16) E6 protein among young women whose HPV 16 infection has become undetectable.

Authors:  Mayumi Nakagawa; Kevin H Kim; Anna-Barbara Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

2.  Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens.

Authors:  M Nakagawa; D P Stites; S Patel; S Farhat; M Scott; N K Hills; J M Palefsky; A B Moscicki
Journal:  J Infect Dis       Date:  2000-07-28       Impact factor: 5.226

3.  CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend.

Authors:  Kevin H Kim; William W Greenfield; Martin J Cannon; Hannah N Coleman; Horace J Spencer; Mayumi Nakagawa
Journal:  Cancer Immunol Immunother       Date:  2011-08-13       Impact factor: 6.968

4.  HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein.

Authors:  Mayumi Nakagawa; Kevin H Kim; Tiffany M Gillam; Anna-Barbara Moscicki
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

5.  Beyond cervical cancer: burden of other HPV-related cancers among men and women.

Authors:  Anil K Chaturvedi
Journal:  J Adolesc Health       Date:  2010-04       Impact factor: 5.012

6.  Epidemiologic classification of human papillomavirus types associated with cervical cancer.

Authors:  Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

7.  Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element.

Authors:  Sytse J Piersma; Marij J P Welters; Jeanette M van der Hulst; Judith N Kloth; Kitty M C Kwappenberg; Baptist J Trimbos; Cornelis J M Melief; Bart W Hellebrekers; Gert Jan Fleuren; Gemma G Kenter; Rienk Offringa; Sjoerd H van der Burg
Journal:  Int J Cancer       Date:  2008-02-01       Impact factor: 7.396

8.  Different methods of identifying new antigenic epitopes of human papillomavirus type 16 E6 and E7 proteins.

Authors:  Mayumi Nakagawa; Kevin H Kim; Anna-Barbara Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2004-09

9.  Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection.

Authors:  Sepideh Farhat; Mayumi Nakagawa; Anna-Barbara Moscicki
Journal:  Int J Gynecol Cancer       Date:  2009-05       Impact factor: 3.437

10.  Human papillomavirus type 16 DNA sequence.

Authors:  K Seedorf; G Krämmer; M Dürst; S Suhai; W G Röwekamp
Journal:  Virology       Date:  1985-08       Impact factor: 3.616

View more
  5 in total

Review 1.  Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines.

Authors:  Mayumi Nakagawa; William Greenfield; Andrea Moerman-Herzog; Hannah N Coleman
Journal:  Clin Vaccine Immunol       Date:  2015-05-06

2.  Developing a Biosensor-Based Immunoassay to Detect HPV E6 Oncoprotein in the Saliva Rinse Fluid of Oral Cancer Patients.

Authors:  Chi-Sheng Cheng; Bor-Rung Ou; Feng-Di Lung
Journal:  J Pers Med       Date:  2022-04-07

3.  Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8+ T Cell Responses.

Authors:  Sue D Xiang; Kirsty L Wilson; Anne Goubier; Arne Heyerick; Magdalena Plebanski
Journal:  Front Immunol       Date:  2018-12-21       Impact factor: 7.561

4.  Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed.

Authors:  Takeo Shibata; Sumit Shah; Teresa Evans; Hannah Coleman; Benjamin J Lieblong; Horace J Spencer; Charles M Quick; Toshiyuki Sasagawa; Owen W Stephens; Erich Peterson; Donald Johann; Yong-Chen Lu; Mayumi Nakagawa
Journal:  Front Immunol       Date:  2021-09-30       Impact factor: 7.561

5.  A novel prostate cancer immunotherapy using prostate-specific antigen peptides and Candida skin test reagent as an adjuvant.

Authors:  Al-Ola Abdallah; Hannah Coleman; Mohamed Kamel; Rodney Davis; Teri Landrum; Horace Spencer; Sam Mackintosh; Fade A Mahmoud; Natasa Milojkovic; Chester Wicker; Konstantinos Arnaoutakis; Mayumi Nakagawa
Journal:  SAGE Open Med       Date:  2018-09-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.